Godavari Biorefineries Limited — Updates, 22-07-2025: Press Release (Revised)

Godavari Biorefineries' biotech arm, Sathgen Therapeutics, has secured a crucial Chinese patent for its novel anti-cancer molecule, HYDROXY-1,4-NAPHTHALENEDIONE. This breakthrough molecule demonstrated strong inhibitory effects on cancer and cancer stem cells in lab studies, showing efficacy against breast and prostate cancer types. This patent strengthens GBL's push into life sciences, building on their green chemistry expertise. With its lead molecule progressing in clinical trials and global patent protection, GBL is deepening its focus on innovative therapies for critical health challenges. A significant step in their diversification and growth.